Paragon 28 To Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
Paragon 28, Inc. (NYSE: FNA) will report financial results for Q4 and full year 2023 on February 29, 2024, with a corresponding conference call. Investors can listen to the call via webcast or phone, with the webcast available for replay on the company's website for at least 90 days.
02/06/2024 - 04:05 PM
ENGLEWOOD, Colo. --(BUSINESS WIRE)--
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 29, 2024. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time.
Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 593140. Live audio of the webcast will be available on the “Investors” section of the company’s website at: ir.paragon28.com . The webcast will be archived and available for replay for at least 90 days after the event.
About Paragon 28, Inc.
Based in Englewood, Colo. , Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206432009/en/
Investor Contact:
Matthew Brinckman
Senior Vice President, Strategy and Investor Relations
Phone: (720) 912-1332
mbrinckman@paragon28.com
Source: Paragon 28, Inc.
When will Paragon 28, Inc. (NYSE: FNA) report financial results for Q4 and full year 2023?
Paragon 28, Inc. (NYSE: FNA) will report financial results for Q4 and full year 2023 after market close on Thursday, February 29, 2024.
How can investors listen to the conference call?
Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 593140.
Where can investors find the webcast replay?
Live audio of the webcast will be available on the “Investors” section of the company’s website at: ir.paragon28.com. The webcast will be archived and available for replay for at least 90 days after the event.
FNA Rankings
#4883 Ranked by Stock Gains
FNA Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Country
US
City
Englewood
About FNA
paragon 28 was established in 2010 as an orthopedic foot and ankle company. the name “paragon 28” was chosen to show that we are exclusively a foot and ankle company, with the “28” representing the number of bones in the foot. we will remain true to that vision. paragon 28 was started as a small, family-based company and we have kept those core ideals as we have grown. our mission is to strategically build a company around the core principles that drive innovation and quality. relentlessly working to advance the science behind foot and ankle surgery, paragon 28 is passionate about and committed to: - creation and innovation: blending different surgical philosophies from various global thought leaders to develop bio-mechanically and clinically relevant surgical solutions. - a focus on service: a customer service based, dedicated, and highly trained distribution network to the foot and ankle market. - efficient practices: meeting the needs of increasing pricing pressures and reimbursemen